Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy.
暂无分享,去创建一个
M. Zile | C. Baicu | Kia N. Zellars | F. Spinale | R. Mukherjee | Robert E. Stroud | Parker D. Freels | William T. Rivers | W. Yarbrough | R. A. McKinney | Corey B Prescott | An O. Van Laer
[1] M. Zile,et al. Myocardial fibroblast-matrix interactions and potential therapeutic targets. , 2014, Journal of molecular and cellular cardiology.
[2] Michael E. Hall,et al. Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling , 2014, Pflügers Archiv - European Journal of Physiology.
[3] Michael E. Hall,et al. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. , 2013, Physiology.
[4] Jeffrey A. Jones,et al. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. , 2012, American journal of physiology. Heart and circulatory physiology.
[5] S. Goruppi,et al. Decreased metalloprotease 9 induction, cardiac fibrosis, and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8. , 2011, American journal of physiology. Cell physiology.
[6] M. Zile,et al. Plasma Biomarkers That Reflect Determinants of Matrix Composition Identify the Presence of Left Ventricular Hypertrophy and Diastolic Heart Failure , 2011, Circulation. Heart failure.
[7] E. Benjamin,et al. Relations of Biomarkers of Extracellular Matrix Remodeling to Incident Cardiovascular Events and Mortality , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[8] C. Rochitte,et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. , 2010, Journal of the American College of Cardiology.
[9] W. Stetler-Stevenson,et al. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. , 2010, Seminars in cancer biology.
[10] V. Regitz-Zagrosek,et al. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[11] R. Khokha,et al. Mice with Tissue Inhibitor of Metalloproteinases 4 (Timp4) Deletion Succumb to Induced Myocardial Infarction but Not to Cardiac Pressure Overload* , 2010, The Journal of Biological Chemistry.
[12] F. Spinale,et al. Cardiac-Restricted Overexpression of Membrane Type-1 Matrix Metalloproteinase in Mice: Effects on Myocardial Remodeling With Aging , 2009, Circulation. Heart failure.
[13] J. Meléndez-Zajgla,et al. Tissue Inhibitor of Metalloproteinases-4. The road less traveled , 2008, Molecular Cancer.
[14] Leslie L. Clark,et al. Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease , 2006, Circulation.
[15] Xu-wen Liu,et al. Novel functions of TIMPs in cell signaling , 2006, Cancer and Metastasis Reviews.
[16] R. Khokha,et al. Combination of Tumor Necrosis Factor-α Ablation and Matrix Metalloproteinase Inhibition Prevents Heart Failure After Pressure Overload in Tissue Inhibitor of Metalloproteinase-3 Knock-Out Mice , 2005, Circulation research.
[17] F. Gao,et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. , 2005, American journal of physiology. Heart and circulatory physiology.
[18] James A. Clark,et al. Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophy , 2005 .
[19] Yan-hong Guo,et al. Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. , 2004, Life sciences.
[20] M. Zile,et al. Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. , 2003, American journal of physiology. Heart and circulatory physiology.
[21] M. Zile,et al. Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition , 2003, Circulation.
[22] Arantxa González,et al. Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.
[23] F. Spinale. Matrix metalloproteinases: regulation and dysregulation in the failing heart. , 2002, Circulation research.
[24] N. Doll,et al. Regression of Left Ventricular Hypertrophy After Surgical Therapy for Aortic Stenosis Is Associated With Changes in Extracellular Matrix Gene Expression , 2001, Circulation.
[25] C. Overall,et al. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. , 2001, Cancer research.
[26] F. Spinale,et al. Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .
[27] B. A. French,et al. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. , 1997, The Journal of clinical investigation.
[28] J. Greene,et al. Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4* , 1996, The Journal of Biological Chemistry.
[29] J. Robbins,et al. Transgenic analysis of the thyroid-responsive elements in the alpha-cardiac myosin heavy chain gene promoter. , 1993, The Journal of biological chemistry.
[30] F. Spinale,et al. Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. , 1991, Circulation research.
[31] O. Hess,et al. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. , 1989, Circulation.
[32] O. Hess,et al. Time course of regression of left ventricular hypertrophy after aortic valve replacement. , 1988, Circulation.
[33] M. Zile,et al. Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. , 2012, The Journal of thoracic and cardiovascular surgery.
[34] K. Brew,et al. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.
[35] M. Zile,et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. , 2000, Journal of molecular and cellular cardiology.
[36] V. Regitz-Zagrosek,et al. Leading article , 1964 .